186 related articles for article (PubMed ID: 9650559)
1. Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay.
De Witte H; Sweep F; Brünner N; Heuvel J; Beex L; Grebenschikov N; Benraad T
Int J Cancer; 1998 Jul; 77(2):236-42. PubMed ID: 9650559
[TBL] [Abstract][Full Text] [Related]
2. ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts.
de Witte H; Pappot H; Brünner N; Grøndahl-Hansen J; Hoyer-Hansen G; Behrendt N; Guldhammer-Skov B; Sweep F; Benraad T; Danø K
Int J Cancer; 1997 Jul; 72(3):416-23. PubMed ID: 9247284
[TBL] [Abstract][Full Text] [Related]
3. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies.
Rønne E; Høyer-Hansen G; Brünner N; Pedersen H; Rank F; Osborne CK; Clark GM; Danø K; Grøndahl-Hansen J
Breast Cancer Res Treat; 1995 Mar; 33(3):199-207. PubMed ID: 7749147
[TBL] [Abstract][Full Text] [Related]
4. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
5. [Dynamic changes in plasma levels of urokinase type plasminogen activator and urokinase type plasminogen activator receptor in patients with systemic inflammatory response syndrome].
Wu XL; Yu L; Long D; Yang JH; Zhang YC; Geng F
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2011 Aug; 23(8):478-81. PubMed ID: 21878172
[TBL] [Abstract][Full Text] [Related]
6. Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients.
Chung HC; Rha SY; Park JO; Yoo NC; Kim JH; Roh JK; Min JS; Lee KS; Kim BS; Kim JJ
Breast Cancer Res Treat; 1998 May; 49(1):41-50. PubMed ID: 9694610
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
8. New ELISA for quantitation of human urokinase receptor (CD87) in cancer.
Kotzsch M; Luther T; Harbeck N; Ockert D; Lutz V; Noack F; Grossmann D; Albrecht S; Kramer MD; Lossnitzer A; Grosser M; Schmitt M; Magdolen V
Int J Oncol; 2000 Oct; 17(4):827-34. PubMed ID: 10995898
[TBL] [Abstract][Full Text] [Related]
9. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer.
Miyake H; Hara I; Yamanaka K; Gohji K; Arakawa S; Kamidono S
Prostate; 1999 May; 39(2):123-9. PubMed ID: 10221568
[TBL] [Abstract][Full Text] [Related]
10. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Shariat SF; Monoski MA; Andrews B; Wheeler TM; Lerner SP; Slawin KM
Urology; 2003 May; 61(5):1053-8. PubMed ID: 12736046
[TBL] [Abstract][Full Text] [Related]
11. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
[TBL] [Abstract][Full Text] [Related]
12. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
13. Expression of urokinase plasminogen activator and its receptor during acute renal allograft rejection.
Roelofs JJ; Rowshani AT; van den Berg JG; Claessen N; Aten J; ten Berge IJ; Weening JJ; Florquin S
Kidney Int; 2003 Nov; 64(5):1845-53. PubMed ID: 14531820
[TBL] [Abstract][Full Text] [Related]
14. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
[TBL] [Abstract][Full Text] [Related]
15. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
[TBL] [Abstract][Full Text] [Related]
16. [Expression of urokinase-type plasminogen activator and its receptor in plasma of patients with cerebral infarction].
Song SJ; Hu JB; Wang HX; Wen SQ; Ding MP; Huang JZ
Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(18):1583-5. PubMed ID: 14642114
[TBL] [Abstract][Full Text] [Related]
17. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
18. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
19. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients.
Pappot H; Høyer-Hansen G; Rønne E; Hansen HH; Brünner N; Danø K; Grøndahl-Hansen J
Eur J Cancer; 1997 May; 33(6):867-72. PubMed ID: 9291807
[TBL] [Abstract][Full Text] [Related]
20. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M
Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
